Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Chantix / Champix [legacy through FY22] by Year
Chantix / Champix (varenicline) [legacy through FY22] ($M) ($M)
Pfizer Chantix / Champix [legacy through FY22]: $8M in FY2022, down 98.0% from a year earlier. No newer figure appears in the documents we track.
Latest, FY2022
8
Period ended Dec 31, 2022
Change on a year earlier
-98.0%
398 in FY2021
History
6 years
Since FY2017
Sources
4
Documents cited below
Where the FY2022 figure comes from
Source: Form 10-K (filed 2023-02-23) ↗
Reported in Form 10-K Segment Note.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Chantix / Champix (varenicline) [legacy through FY22] ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2022 | Dec 31, 2022 | 8 | -98.0% | Form 10-K (filed 2023-02-23) ↗ |
| FY2021 | Dec 31, 2021 | 398 | -56.7% | Form 10-K (filed 2023-02-23) ↗ |
| FY2020 | Dec 31, 2020 | 919 | -17.0% | Form 10-K (filed 2023-02-23) ↗ |
| FY2019 | Dec 31, 2019 | 1,107 | +2.0% | Form 10-K (filed 2022-02-24) ↗ |
| FY2018 | Dec 31, 2018 | 1,085 | +8.8% | Form 10-K (filed 2021-02-25) ↗ |
| FY2017 | Dec 31, 2017 | 997 | – | Form 10-K (filed 2020-02-27) ↗ |
Cite this data
StockData. (2026). Pfizer Chantix / Champix [legacy through FY22] ($M), annual FY2017–FY2022 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/chantix-leg
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.